Central nervous system infections in individuals with HIV-1 infection

Journal of NeuroVirology

Volumn 8, Issue 3, 2002, Pages 158-167

  Mamidi, Arunima ^a   DeSimone, Joseph A ^a   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cryptococcal meningitis; Cytomegalovirus encephalitis; Human immunodeficiency virus type 1; Progressive multifocal leukoencephalopathy; Toxoplasma encephalitis

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATOVAQUONE; AZITHROMYCIN; CIDOFOVIR; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; CYTARABINE; DAPSONE; DNA TOPOISOMERASE INHIBITOR; FANSIDAR; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARIN; HYDROXYUREA; ITRACONAZOLE; MALOPRIM; PROTEINASE INHIBITOR; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FUNGAL MENINGITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYMPTOMATOLOGY; TOXOPLASMOSIS; VIRUS ENCEPHALITIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CYTOMEGALOVIRUS INFECTIONS; HIV-1; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LYMPHOMA, AIDS-RELATED; MENINGITIS, CRYPTOCOCCAL; TOXOPLASMOSIS;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; TOXOPLASMA;

EID: 0036301058     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280290049723     Document Type: Review

References (94)

1. HAART significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy
2. Epstein-Barr virus in monitoring the response to therapy of acquired immunodeficiency syndrome-related primary central nervous system lymphoma
3. Detection of Epstein-Barr virus DNA in cerebrospinal fluid for diagnosis of AIDS-related central nervous system lymphoma
4. Level of CMV DNA in cerebrospinal fluid of subjects with AIDS and CMV infection in the central nervous system
5. Progressive multifocal leukoencephalopathy
6. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection
7. Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy
8. Progressive multifocal leukoencephalopathy in patients with HIV infection
9. The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir
10. Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy
11. AIDS-related central nervous system lymphomas
12. Brain lesions in patients with AIDS: H-1 MR spectroscopy
13. GA/GC-rich sequence confers Tat responsiveness to human neurotropic virus promoter, JCV, in cells derived from central nervous system
14. PCR detection of Toxoplasma gondii DNA in CSF for the differential diagnosis of AIDS-related focal brain lesions
15. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma
16. Ganciclovir therapy for cytomegalovirus infection of the central nervous system in AIDS patients: Monitoring by CMV DNA detection in cerebrospinal fluid
17. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients
18. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients
19. Magnetic resonance brain imaging lacks sensitivity for AIDS associated cytomegalovirus encephalitis
20. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy
21. Neurologic manifestations of toxoplasmosis in AIDS
22. Performance status and age as independent predictors of survival among AIDS patients with primary CNS lymphoma: A multivariate analysis of a multi-institutional experience
23. Treatment of toxoplasmic encephalitis in patients with AIDS
24. Improved detection of JC virus DNA in cerebrospinal fluid for diagnosis of AIDS-related progressive multifocal leukoencephalopathy
25. Clinical and virological monitoring during treatment with intathecal cytarabine in patients with AIDS-associated progressive multifocal leukoencephalopathy
26. Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy
27. Adult and Adolescent Spectrum of HIV Disease Project Progressive multifocal leukoencephalopathy: Improved survival of HIV-infected patients in the protease inhibitor era
28. PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy
29. Management of elevated intracranial pressure in patients with cryptococcal meningitis
30. Primary central nervous system lymphoma
31. AIDS primary central nervous system lymphoma
32. The natural history of progressive multifocal leukoencephalopathy in patients with AIDS
33. Clinical correlates of secondary meningitis in HIV-infected adults
34. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
35. Zidovudine epidemiology group Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine
36. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection
37. Exogenous tat protein activates central nervous system-derived endothelial cells
38. Cytomegalovirus encephalitis in AIDS
39. Epidemiology of progressive multifocal leukoencephalopathy in the United States
40. Cytomegalovirus ventriculoencephalitis in AIDS
41. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy
42. Progressive multifocal leukoencephalopathy: Clinical and radiographic features
43. Human immunodeficiency virus-1 infection of the nervous system
44. Microscopy and latex antigen negative cryptococcal meningitis
45. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
46. HIV-1-related neurologic disorders
47. Toxoplasmic encephalitis in AIDS
48. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain
49. ACTG 363 team Prospective pilot study of cidofovir for HIV-associated progressive multifocal leukoencephalopathy
50. Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients responding to highly active antiretroviral therapy
51. Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS
52. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy
53. Detection of JC virus DNA in human tonsil tissue: Evidence for site of initial viral infection
54. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome
55. Toxoplasmosis
56. Risk factors for cryptococcal meningitis in HIV-infected patients
57. Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy
58. Detection of polyomaviral DNA in clinical samples from immunocompromised patients: Correlation with clinical disease
59. Neuropathology of acquired immunodeficiency syndrome: An autopsy review
60. Evaluating contrast-enhancing brain lesions in patients with AIDS by using positron emission tomography
61. Intrathecal production of antibodies against Toxoplasma gondii in patients with toxoplasmic encephalitis and the acquired immunodeficiency syndrome (AIDS)
62. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: Alterations of the blood-brain barrier
63. Ganciclovir treatment of cytomegalovirus ventriculitis in a patient infected with human immunodeficiency virus
64. Potential role for granulocyte-macrophage colony-stimulating factor in the treatment of HIV-associated cryptococcal meningitis
65. Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL)
66. Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome
67. Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis
68. Primary central nervous system lymphoma in patients with AIDS
69. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis
70. Practice guidelines for the management of cryptococcal disease
71. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS
72. Management of intracerebral lesions in patients with HIV: A retrospective study with discussion of diagnostic problems
73. New treatments for progressive multifocal leukoencephalopathy in HIV-1-infected patients
74. Cytomegalovirus ventriculoencephalitis in AIDS patients
75. Intracerebral mass lesions in patients with human immunodeficiency virus infection and cryptococcal meningitis
76. Dual infective pathology in patients with cryptococcal meningitis
77. Neurologic manifestation of HIV infection
78. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system
79. Treatment of AIDS-related lymphomas
80. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells
81. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy
82. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors
83. Progressive multifocal leukoencephalopathy
84. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy
85. JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects
86. Cytomegalovirus in the nervous system of patients with acquired immunodeficiency syndrome
87. Neuroimaging findings in patients with AIDS
88. Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction
89. Progressive mutifocal leukoencephalopathy in 47 HIV-seropositive patients: Neuroimaging with clinical and pathologic correlation
90. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS
91. HIV combination therapy: Partial immune restitution unmasking latent cryptococcal infection
92. Central nervous system opportunistic infections
93. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy
94. Cryptococcal meningitis in patients with the acquired immunodeficiency syndrome